one step ahead

Writing the next chapter of growth

Capital Markets Day 2026

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026



Program

Welcome	
Opening remarks: strategy and “Agenda 2030”	David Veitch | CEO
Fungal infections: why we still need differentiated treatment options	Professor Oliver Cornely
New developments in the treatment of Gram-negative bacterial infections	Professor David Paterson
Coffee break	
R&D pipeline update: addressing medical need	Marc Engelhardt | CMO
Panel discussion with CMO and expert speakers	CMO & Experts
Business model, financials and growth opportunities	Adesh Kaul | CFO
Q&A session with CEO, CFO and CMO	
Closing remarks and key takeaways	David Veitch | CEO
Networking reception	



basilea

Opening remarks:

Strategy and “Agenda 2030”

Capital Markets Day 2026



David Veitch

Chief Executive Officer

basilea

David Veitch

Chief Executive Officer

"Basilea is in a position of strength"


basilea

basilea

What defines Basilea is that we always aim to be **one step ahead**

basilea

one step ahead in Innovation

basilea

one step ahead in

Collaboration

basilea

one step ahead in

Patient care

basilea

one step ahead in

Leadership

basilea

one step ahead in

Growth

Introducing Basilea

Founded as a spin off from Roche in


2000

Profitable Swiss commercial-stage

biopharmaceutical company

About

200



employees

Focused on developing treatments for severe

bacterial & fungal infections



Listed on the SIX Swiss Stock Exchange, Ticker:

BSLN.SW

Headquarters in Allschwil, Switzerland, in the



Basel area

life sciences hub

basilea

In 2022, we set a clear ambition: to become a leading anti-infectives company

basilea

Our goals in 2022

Delivering on our goals

Our achievements

Delivering on our goals

Our goal in 2022

Build a clinical pipeline

Our achievement

Pipeline expanded with 4 new assets added from 2023–2025, creating mid-term value drivers

Delivering on our goals

Our goal in 2022

Create
a financially
sustainable
anti-infectives
business

Our achievement

Sustainable positive operating cash flow and significantly reduced debt

Delivering on our goals

Our goal in 2022

Accessing the US market with Zevtera

Our achievement

FDA approval achieved & experienced commercial partner secured


basilea

We delivered on our goals...

...and built the foundation for our next chapter

The right business model

External pool of potential assets



Non-dilutive funding & support

BARDA
CARB-X




Basilea today

In a position of strength

Addressing urgent and evolving infection threats

Clinical




Financial strength

in CHF million, rounding consistently applied

Full year 2025

Total revenue

232.4 +11.4% year-on-year



38.0 Other revenue

Cresemba & Zevtera related revenue

194.4 −0.2% year-on-year

Thereof royalty income

111.6 +15.4% year-on-year

Financial strength

in CHF million, rounding consistently applied

Half year 2026

Total revenue



119.0

+ 14.4%
year-on-year

Net cash

105.3

+107.7%
year-on-year

Cash and cash equivalents and restricted cash

176.0

+32.6%
year-on-year

Basilea today — In a position of strength



basilea

Partners:

ADVANZ PHARMA

AsahiKASEI THERAPEUTICS

astellas

AVIR PHARMA

CR Gosun

hikma.

INNOVIVA Specialty Therapeutics

UKnight

LANCET

Pfizer

UNIMEDIC PHARMA

Proven ability to access significant non-dilutive funding

by BARDA and CARB-X committed

~440 million

out of which awarded


~165 million

basilea

Agenda 2030

Where do we aim to be by 2030, and how will we get there

basilea



Agenda 2030

Mid-term value creation

Agenda 2030

Basilea well positioned for sustainable growth

Strong financial position



CHF 160 million cash as of end-2025

Approx. CHF 600 million cumulative cash flow from Cresemba and Zevtera from 2026 to 2030

More than USD 350 million potential non-dilutive funding from existing agreements (committed and potential future tranches)

This allows us to



Bring late-stage assets to market targeting four commercial products by 2030

Advance early-stage pipeline

In-license or acquire exciting new assets to build an industry-leading R&D pipeline

Agenda 2030

Basilea's roadmap for the next growth phase and value creation

Strategic priority


01


Operating out of a strong financial position

CHF **160** million
cash as of end-2025

~CHF **600** million
expected cumulative cash flow

from Cresemba and Zevtera (2026–2030)





plus more than USD **350** million in potential additional

non-dilutive R&D funding (2026–2030)


Agenda 2030

Basilea's roadmap for the next growth phase and value creation

Strategic priority

02

Broadening the commercial portfolio




Agenda 2030

Basilea's roadmap for the next growth phase and value creation

Strategic priority

03

Keep building an industry leading pipeline through BD&L



Agenda 2030

Basilea is well positioned for sustainable value creation

600 million
cash flow
from current commercial portfolio
Cumulative 2026–2030


BD&L
Ongoing priority through 2030


Agenda 2030
Mid-term value creation

CTB-LEDA
Phase 2/3 readouts

Fosmanogepix
Phase 3 readout

Non-dilutive funding
Expected through 2030





basilea
Next horizon
By 2030, multiple revenue streams and growth drivers will reduce single-asset dependency and significantly enhance Basilea's growth profile, resilience, and value



Why anti-infectives still matter

Severe bacterial and fungal infections continue to carry a high burden — with significant unmet medical need


basilea
7.7
million
people
die every year due to
bacterial infections


basilea
6.5 million people
are affected by invasive fungal infections every year
and 3.8 million people die, with 2.5 million deaths directly attributable to that fungal disease

High disease burden, rising resistance and limited treatment options create a continuing need for innovation in anti-infectives

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026



Fungal infections: why we still need differentiated treatment options

Capital Markets Day 2026

basilea

Oliver A. Cornely

Professor of Translational Research,
Faculty of Medicine, University of Cologne



one step ahead

Writing the next chapter of growth

Capital Markets Day 2026



New developments in the treatment of Gram-negative bacterial infections

Capital Markets Day 2026



basilea

David Paterson

Professor ADVANCE-ID,
National University of Singapore

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026



R&D pipeline update:

Addressing medical need

Capital Markets Day 2026



Marc Engelhardt, M.D.

Chief Medical Officer

basilea

Significant need

for new treatments

Significant need for new treatments

Efficacy



- Novel mechanisms of action
- Broader spectrum of coverage
- Addressing resistance development

Safety



- Improved safety profile
- Suitable for long-term treatment
- Improved drug interaction profiles

Practical



- Oral treatment options
- No food restrictions
- Convenient administration

These needs continue to create attractive opportunities for differentiated innovation in anti-infectives

Two late-stage opportunities to address significant unmet need

Both assets meet our criteria

- Fosmanogepix
- Ceftibuten-ledaborbactam

basilea

Fosmanogepix

First-in-class broad-spectrum antifungal

Fosmanogepix

First-in-class broad-spectrum antifungal

Growing clinical experience

Clinical studies and
Expanded Access Program

Phase 3 development underway

Two studies in invasive mold
and invasive yeast infections

Strong external support

QIDP, Fast Track and
Orphan Drug designations;
BARDA funding

Focused on serious invasive fungal infections where new treatment options are needed.



Fosmanogepix

Key attributes and differentiators

01

Active against most clinically relevant molds and yeasts

02

Wide tissue distribution

03


IV and oral formulations

04

New mode of action

Fosmanogepix


New mode of action leading to fungal cell death



Fosmanogepix

Real-world evidence builds confidence in fosmanogepix' potential


- Expanded Access Program for patients with serious and/or life-threatening invasive fungal infections with no other treatment option
- About 600 patients treated across 22 countries since 2020



Fosmanogepix

Real-world evidence builds confidence in fosmanogepix' potential

A broad-spectrum antifungal, backed by real-world clinical experience



basilea

Fosmanogepix

Significant medical need supports a substantial market opportunity

Fosmanogepix

Significant medical need supports a substantial market opportunity

Commercial success of antifungals

Cresemba (isavuconazole)

Global sales already

817 million USD*

Vfend (voriconazole)

Global sales

825 million USD* (LOE 2010)

Commercial potential

Basilea's fosmanogepix

potential peak sales

~1 billion USD

*Source: IQVIA Analytics Link, June 2026. Reminder: Antibacterials sales typically peak around loss of exclusivity (LOE), which has not yet been reached for Cresemba.


basilea
The persistent burden of invasive fungal infections and limited treatment innovation continue to
create opportunities
for differentiated new therapies

Two late-stage opportunities to address significant unmet need

Both assets meet our criteria

- Fosmanogepix
- Ceftibuten-ledaborbactam

basilea

Ceftibuten-ledaborbactam

addressing the need for an oral treatment for resistant Gram-negative infections

Ceftibuten-ledaborbactam

Ceftibuten-ledaborbactam

Targeting resistant Gram-negative bacteria

Established concept

Combines ceftibuten (beta-lactam; BL) with ledaborbactam (beta-lactamase inhibitor; BLI)

Relevant spectrum

Active against key resistant pathogens, including ESBL producers and CRE[1]

Oral BL/BLI option

Designed as an oral BL/BLI option for resistant Gram-negative pathogens

Late-stage development

Registrational program in cUTI planned for mid-2027

QIDP and Fast Track designations[2]

BARDA-supported development

Phase 2/3

[1] Ledaborbactam restores ceftibuten activity against Enterobacterales producing Ambler Class A, C and D ESBLs and carbapenemases (including pathogens designated as critical threats in the WHO Priority Pathogen List, 2024; [2] QIDP and Fast Track designations by the FDA for cUTI and uncomplicated urinary tract infections

Ceftibuten-ledaborbactam

cUTI: A significant and growing unmet medical need


Pathogen distribution in cUTI[1]

75%

caused by Enterobacterales

15–20%

of Enterobacterales urinary isolates now ESBL-producing[2]



[1] Lodise TP, et al. Open Forum Infect Dis. 2022;9(7):ofac315.
[2] CDC AR Threats Report; IDSA 2024 AMR Guidance; peer-reviewed US surveillance studies (see appendix); Adapted from Flores-Mireles et al. Nat Rev Microbiol. 2015;13(5):269-84.

basilea

Why oral treatment matters

Why oral treatment matters

Oral therapy has the potential to improve patient convenience while reducing healthcare burden

Current standard of care

- IV therapy
- Hospitalization or infusion-center resources
- Longer length of hospital stay drives higher cost

Why oral treatment matters

Oral therapy has the potential to improve patient convenience while reducing healthcare burden

Potential benefit of an oral BL/BLI treatment

- Enables outpatient treatment
- Reduced healthcare resource utilization
- Shorter and less costly care
- Supports antimicrobial stewardship (reduced carbapenem usage)

A validated market

Commercial success of newer Gram-negative IV-only antibiotics:

Avycaz (ceftazidime-avibactam)

Global sales

746 million USD*

Fetroja (cefiderocol)

Global sales

339 million USD*

Zerbaxa (ceftolozane/tazobactam)

Global sales

310 million USD*

Commercial potential

Ceftibuten-ledaborbactam

Potential peak sales

~500 million USD

*Source: IQVIA Analytics Link, June 2026. Reminder: Antibiotics sales typically peak around loss of exclusivity (LOE), which has not yet been reached.

Two late-stage opportunities to address significant unmet need

Both assets meet our criteria

- Fosmanogepix
- Ceftibuten-ledaborbactam

Advancing our late-stage programs toward approval

Ceftibuten-ledaborbactam

Global phase 2/3 program targeting an unrestricted label

- Complicated urinary tract infections[1] — Phase 3 data readout

★ Phase 2 data readout

Fosmanogepix

Global phase 3 program derisked through positive real-world data

- FAST IC Study — Invasive candidiasis and candidemia[2]
- FORWARD IM Study — Invasive mold infections[3]

Phase 3 data readout



[1] Includes pyelonephritis; [2] ClinicalTrials.gov ID: NCT05421858; [3] ClinicalTrials.gov ID: NCT06925321

Early-stage clinical pipeline


Antibacterial and antifungal assets

BAL2062

Phase 2 candidate

- Novel antifungal for invasive aspergillosis, including resistant strains
- New mode of action with potential efficacy advantages
- Encouraging phase 1 safety and tolerability profile
- Development supported by BARDA

BAL2062 uptake leads to fungal cell death



Early-stage clinical pipeline


Antibacterial and antifungal assets

BAL2420

Phase 1 candidate

- Antibiotic with novel mode of action
- Addresses the most frequent Gram-negative pathogens causing infections (Enterobacteriaceae), including carbapenem-resistant isolates
- First-in-human phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics expected to complete in H1 2027
- Development supported by CARB-X

BAL2420 destroys the LPS transport bridge



one step ahead

Writing the next chapter of growth

Capital Markets Day 2026

basilea

Panel discussion

Chief Medical Officer and Expert Speakers

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026



Business model, financials and growth opportunities

Capital Markets Day 2026



Adesh Kaul

Chief Financial Officer

basilea

one step ahead

requires more than the right opportunities...

basilea

one step ahead
requires more than the right
opportunities...

...it requires the financial strength to act on them

Financial strength underpins the execution of “Agenda 2030”

01 Operating out of a strong financial position

02 Broadening the commercial portfolio

03 Keep building on industry leading pipeline through BD&L


Supported by a strong financial foundation

- Cash generation from the current commercial portfolio
- Non-dilutive funding
- Strong cash position

Cash generation from the current commercial portfolio

Cresemba maintains strong momentum

– In-market sales continue double-digit growth




USD

817 million

July 2025 to June 2026

25%

year-on-year growth



MAT: Moving annual total; Source: IQVIA Analytics Link, June 2026

Cash generation from the current commercial portfolio

Cresemba® – Global market leader in terms of value

Continued growth opportunity for the brand:

Growth in the US
until Q4 2027

Growth in Europe
until H2 2028

Growth in Japan and other markets
beyond 2028

Cash generation from the current commercial portfolio

Zevtera® US launch – Positioned for future success

Launched in the US in July 2025 with Innoviva Specialty Therapeutics



Broad market access

established

Expanded hospital

coverage

Positive early adoption

and repeat ordering

Market exclusivity

through April 2034 supports long-term growth

Cash generation from the current commercial portfolio

Durability and strength of our commercial business

Cash flows from Cresemba and Zevtera

CHF 600 million

2026–2030 cumulative target

2026 2027 2028 2029 **2030**

Cash generation from the current commercial portfolio

Durability and strength of our commercial business

Cash flows from Cresemba and Zevtera

Guided for

210 CHF million

in Cresemba- and Zevtera-related revenue

2026

2027 2028 2029 2030

Cash generation from the current commercial portfolio

Durability and strength of our commercial business

-30 CHF million

Cost of Products Sold

2026 2027 2028 2029 2030

Cash generation from the current commercial portfolio

Durability and strength of our commercial business

Guided for

180 CHF million

Cash flows from Cresemba and Zevtera

30%

of our target after year 1

2026 2027 2028 2029 2030

Non-dilutive funding

R&D investments significantly offset through non-dilutive R&D funding

by BARDA and CARB-X committed



> 440 million

out of which expected in 2026-2030



~350 million

Strong cash position

Strong balance sheet

CHF 71 million remaining debt – expected to be **debt-free in 2027**

No financing need

Cash, restricted cash and cash equivalents
As of June 30, 2026

CHF

176 million

basilea

Cresemba and Zevtera make a meaningful difference to patients worldwide

Global reach and patient impact



basilea

Partners:

ADVANZ PHARMA

AsahiKASEI THERAPEUTICS

astellas

AVIR PHARMA

CR Gosun

hikma.

INNOVIVA Specialty Therapeutics

UKnight

LANCET

Pfizer

UNIMEDIC PHARMA

Global reach and patient impact

basilea

>70

Countries

Cresemba and Zevtera commercially available to patients worldwide

>600k

Patients treated

with Cresemba and Zevtera worldwide, including pediatric patients

11

Commercial partners

Extending access to Basilea medicines worldwide



Delivering meaningful patient impact through a financially sustainable commercialization model enhances our attractiveness as a BD&L partner of choice

basilea

Pipeline expansion through disciplined BD&L

Pipeline expansion through disciplined BD&L

Our acquisition criteria

Strategic fit

Fits our anti-infectives expertise

Medical need

Relevant unmet need

Clinical differentiation

Better outcomes or meaningful advantages

Regulatory pathway

Achievable development path

Commercial potential

Attractive future economics

We will deliver on our Agenda 2030

We are in a great position to deliver on our “Agenda 2030” priorities

01 Operating out of a strong financial position

02 Broadening the commercial portfolio

03 Keep building on industry leading pipeline through BD&L

- Fosmanogepix Phase 3 readout expected mid-2028
- CTB-LEDA Phase 2/3 start planned for mid-2027
- Early-stage clinical pipeline
- Strong anti-infectives track record
- Financial strength and flexibility

We will deliver on our Agenda 2030

We are in a great position to deliver on our “Agenda 2030” priorities

- Cash generation from the current commercial portfolio
- Non-dilutive funding
- Strong cash position

Cumulative cash flow from Cresemba and Zevtera, 2026–2030

~600 million CHF

Non-dilutive funding

~350 million USD

Cash as of end-2025

160 million CHF

Updated Agenda 2030 cash flow target

Cash generation from the current commercial portfolio

Cumulative cash flow from Cresemba and Zevtera, 2026–2030

~ 650 million CHF

215 million CHF

achieved by end-2026

Updated FY 2026 financial guidance – Increase in total revenue driving significant increase in operating profit

in CHF million	**FY 2026** updated guidance	**FY 2026** previous guidance	**FY 2025** actuals
Cresemba and Zevtera related revenue	~250	~210	194.4
of which royalty income	*~130*	*~125*	*111.6*
Total revenue	**~310 (~ 33% increase)**	~ 15% increase	***232.4***
Research and development expenses	~125 (~ 18% increase)	~ 20% increase	105.9
Operating profit	**~115 (~ 123% increase)**	~ 40% increase	***51.5***

Note: Consistent rounding was applied.

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026

basilea

Q&A session

with CEO, CFO and CMO

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026



Closing remarks & key takeaways

Capital Markets Day 2026

Why Basilea will succeed

Why Basilea will succeed

Agenda 2030

Non-dilutive funding


Fosmanogepix
Phase 3 readout

CTB-LEDA
Phase 2/3 readouts

650 million
cash flow
from current commercial portfolio

BD&L

Agenda 2030
Mid-term value creation



basilea

Our aim is to succeed in delivering on Agenda 2030 and beyond

Basilea: A clear path to sustained growth and value creation

Sustained growth and value creation

01 Profitable today

02 Financially strong

03 Leading in our market

04 Significant pipeline upside

05 Capital-efficient & scalable

basilea

one step ahead

basilea

one step ahead in Innovation

basilea

one step ahead in

Collaboration

basilea

one step ahead in

Patient care

basilea

one step ahead in

Leadership

basilea

one step ahead in

Growth

Thank you

Capital Markets Day 2026

one step ahead

Writing the next chapter of growth

Capital Markets Day 2026